SARASOTA, Fla., August 10, 2026
Silo Pharma, Inc. announced that the European Patent Office (EPO) has granted a patent covering the preventative therapeutic approach of SPC-15, the company’s investigational intranasal, nose-to-brain treatment being developed for post-traumatic stress disorder (PTSD) and other stress-induced affective disorders. European Patent No. EP3952852, titled “Prophylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress,” covers methods designed to prevent stress-induced fear, depressive-like behavior and associated psychiatric disorders by administering selected serotonin 4 (5-HT4) receptor agonists before exposure to a significant stressor. The patent strengthens the intellectual property position of SPC-15 in Europe and represents an important development for Silo Pharma as it advances a therapeutic strategy aimed at intervening before PTSD symptoms develop, rather than treating established symptoms after traumatic exposure. Silo holds an exclusive license from Columbia University covering the development, manufacturing and commercialization of SPC-15 globally.
European Patent Strengthens SPC-15 Intellectual Property
The newly granted European patent provides additional protection for the prophylactic use of 5-HT4 receptor agonists against stress-related psychiatric effects and expands the intellectual property portfolio supporting SPC-15. Silo Pharma said the European protection complements patent rights that have already been granted or remain pending in five other major global markets, creating a broader international framework around the program. The approach underlying SPC-15 is differentiated from conventional PTSD treatments because it is designed to influence biological pathways associated with stress resilience and prevention before a traumatic or highly stressful event produces persistent psychiatric consequences. The company believes this strategy could have potential applications for populations considered to be at elevated risk of trauma exposure, although the therapeutic concept remains investigational and its clinical effectiveness and safety will need to be established through appropriate studies. The European patent itself does not establish clinical efficacy or regulatory approval for SPC-15, but it can provide important commercial and development protection as the program progresses.
SPC-15 Targets Stress-Related Psychiatric Disorders
SPC-15 is being developed as an intranasal, nose-to-brain therapeutic candidate targeting PTSD and stress-induced affective disorders. The program is based on modulation of the 5-HT4 receptor, with the objective of influencing mechanisms involved in the brain’s response to severe stress. Silo Pharma has described the program as a potential new approach to PTSD prevention because current treatment strategies generally focus on managing symptoms after the disorder has emerged. If successfully developed, a preventative therapy could potentially have relevance for individuals facing predictable or high-risk exposure to extreme stress, although that potential remains to be demonstrated in human clinical development. The company’s exclusive agreement with Columbia University gives Silo rights to further develop, manufacture and commercialize SPC-15, while the expanding patent estate is intended to protect the underlying therapeutic approach across multiple geographic markets. The latest European grant therefore represents an intellectual property milestone, rather than a clinical or regulatory approval milestone.
Advertisement
Silo Pharma Advances Broader Therapeutic Pipeline
Beyond SPC-15, Silo Pharma is advancing a diversified developmental-stage pipeline focused on underserved conditions involving the central nervous system, chronic pain and stress-related disorders. The company’s portfolio includes SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and a preclinical program targeting Alzheimer’s disease. Silo Pharma is also pursuing technology initiatives through its wholly owned QwikAgents subsidiary, while maintaining its biopharmaceutical programs as a core component of its strategy. The European patent grant adds further protection to SPC-15 at a time when interest in novel approaches to psychiatric disease continues to increase, particularly strategies aimed at addressing disease biology rather than relying solely on symptom management. However, the commercial and clinical value of SPC-15 will ultimately depend on future preclinical and clinical evidence, regulatory progress and demonstrated patient benefit. For now, the EPO decision strengthens Silo Pharma’s global intellectual property position and supports continued development of its preventative PTSD therapeutic strategy
Source:Silo Pharma press release
